Novel observations with FDOPA‐PET imaging after early nigrostriatal damage
Identifieur interne : 000534 ( Istex/Corpus ); précédent : 000533; suivant : 000535Novel observations with FDOPA‐PET imaging after early nigrostriatal damage
Auteurs : R. E. Yee ; I. Irwin ; C. Milonas ; D. B. Stout ; S-C. Huang ; K. Shoghi-Jadid ; N. Satyamurthy ; L. E. Delanney ; D. M. Togasaki ; K. F. Farahani ; K. Delfani ; A. M. Janson ; M. E. Phelps ; J. W. Langston ; J. R. BarrioSource :
- Movement Disorders [ 0885-3185 ] ; 2001-09.
English descriptors
- KwdEn :
Abstract
Striatal 6‐[18F]fluoro‐L‐DOPA (FDOPA) kinetic rate constants were measured by positron emission tomography (PET) in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐treated squirrel monkeys. After scanning, stereological counts of dopaminergic neurons were done in substantia nigra, and dopamine (DA) and metabolite concentrations were determined in the caudate, putamen, and substantia nigra. Graded doses of MPTP produced animals with mild to moderate reductions (10–35%) in dopaminergic neurons, where the percent of cell loss was proportional to the amount of MPTP given. Striatal DA and metabolite concentrations were relatively unchanged in animals given 1.0 and 1.5 mg/kg of MPTP, but were significantly reduced after 2.0 mg/kg of MPTP. All animals injected with a single dose of MPTP showed no overt signs of parkinsonism. In contrast, DA and metabolite concentrations in the substantia nigra were significantly reduced for all MPTP‐treated animals. Reduction of dopaminergic indices in the substantia nigra did not parallel reductions in the striatum, indicating differential sensitivity of the nigrostriatal pathway to the neurotoxic effects of MPTP. The percent change in FDOPA uptake (Ki) and decarboyxlation (k3) after MPTP showed significant positive correlations to striatal DA levels, but not to the number of dopaminergic neurons. This suggests that FDOPA is a good index of striatal DA levels. © 2001 Movement Disorder Society.
Url:
DOI: 10.1002/mds.1168
Links to Exploration step
ISTEX:30BF6B3FD3C05C2EEA0624BCFD1583FA06C06E27Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Novel observations with FDOPA‐PET imaging after early nigrostriatal damage</title><author><name sortKey="Yee, R E" sort="Yee, R E" uniqKey="Yee R" first="R. E." last="Yee">R. E. Yee</name><affiliation><mods:affiliation>Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Irwin, I" sort="Irwin, I" uniqKey="Irwin I" first="I." last="Irwin">I. Irwin</name><affiliation><mods:affiliation>The Parkinson's Institute, Sunnyvale, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Milonas, C" sort="Milonas, C" uniqKey="Milonas C" first="C." last="Milonas">C. Milonas</name><affiliation><mods:affiliation>Department of Neuroscience, Karolinska Institute, Stockholm, Sweden</mods:affiliation></affiliation></author><author><name sortKey="Stout, D B" sort="Stout, D B" uniqKey="Stout D" first="D. B." last="Stout">D. B. Stout</name><affiliation><mods:affiliation>Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Huang, S" sort="Huang, S" uniqKey="Huang S" first="S-C." last="Huang">S-C. Huang</name><affiliation><mods:affiliation>Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Biomathematics, UCLA School of Medicine, Los Angeles, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Shoghi Adid, K" sort="Shoghi Adid, K" uniqKey="Shoghi Adid K" first="K." last="Shoghi-Jadid">K. Shoghi-Jadid</name><affiliation><mods:affiliation>Department of Biomathematics, UCLA School of Medicine, Los Angeles, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Satyamurthy, N" sort="Satyamurthy, N" uniqKey="Satyamurthy N" first="N." last="Satyamurthy">N. Satyamurthy</name><affiliation><mods:affiliation>Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Delanney, L E" sort="Delanney, L E" uniqKey="Delanney L" first="L. E." last="Delanney">L. E. Delanney</name><affiliation><mods:affiliation>The Parkinson's Institute, Sunnyvale, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Togasaki, D M" sort="Togasaki, D M" uniqKey="Togasaki D" first="D. M." last="Togasaki">D. M. Togasaki</name><affiliation><mods:affiliation>The Parkinson's Institute, Sunnyvale, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Farahani, K F" sort="Farahani, K F" uniqKey="Farahani K" first="K. F." last="Farahani">K. F. Farahani</name><affiliation><mods:affiliation>Department of Radiological Sciences, UCLA School of Medicine, Los Angeles, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Delfani, K" sort="Delfani, K" uniqKey="Delfani K" first="K." last="Delfani">K. Delfani</name><affiliation><mods:affiliation>Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Janson, A M" sort="Janson, A M" uniqKey="Janson A" first="A. M." last="Janson">A. M. Janson</name><affiliation><mods:affiliation>Department of Neuroscience, Karolinska Institute, Stockholm, Sweden</mods:affiliation></affiliation></author><author><name sortKey="Phelps, M E" sort="Phelps, M E" uniqKey="Phelps M" first="M. E." last="Phelps">M. E. Phelps</name><affiliation><mods:affiliation>Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Langston, J W" sort="Langston, J W" uniqKey="Langston J" first="J. W." last="Langston">J. W. Langston</name><affiliation><mods:affiliation>The Parkinson's Institute, Sunnyvale, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Barrio, J R" sort="Barrio, J R" uniqKey="Barrio J" first="J. R." last="Barrio">J. R. Barrio</name><affiliation><mods:affiliation>Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:30BF6B3FD3C05C2EEA0624BCFD1583FA06C06E27</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1002/mds.1168</idno><idno type="url">https://api.istex.fr/document/30BF6B3FD3C05C2EEA0624BCFD1583FA06C06E27/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000534</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Novel observations with FDOPA‐PET imaging after early nigrostriatal damage</title><author><name sortKey="Yee, R E" sort="Yee, R E" uniqKey="Yee R" first="R. E." last="Yee">R. E. Yee</name><affiliation><mods:affiliation>Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Irwin, I" sort="Irwin, I" uniqKey="Irwin I" first="I." last="Irwin">I. Irwin</name><affiliation><mods:affiliation>The Parkinson's Institute, Sunnyvale, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Milonas, C" sort="Milonas, C" uniqKey="Milonas C" first="C." last="Milonas">C. Milonas</name><affiliation><mods:affiliation>Department of Neuroscience, Karolinska Institute, Stockholm, Sweden</mods:affiliation></affiliation></author><author><name sortKey="Stout, D B" sort="Stout, D B" uniqKey="Stout D" first="D. B." last="Stout">D. B. Stout</name><affiliation><mods:affiliation>Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Huang, S" sort="Huang, S" uniqKey="Huang S" first="S-C." last="Huang">S-C. Huang</name><affiliation><mods:affiliation>Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Biomathematics, UCLA School of Medicine, Los Angeles, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Shoghi Adid, K" sort="Shoghi Adid, K" uniqKey="Shoghi Adid K" first="K." last="Shoghi-Jadid">K. Shoghi-Jadid</name><affiliation><mods:affiliation>Department of Biomathematics, UCLA School of Medicine, Los Angeles, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Satyamurthy, N" sort="Satyamurthy, N" uniqKey="Satyamurthy N" first="N." last="Satyamurthy">N. Satyamurthy</name><affiliation><mods:affiliation>Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Delanney, L E" sort="Delanney, L E" uniqKey="Delanney L" first="L. E." last="Delanney">L. E. Delanney</name><affiliation><mods:affiliation>The Parkinson's Institute, Sunnyvale, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Togasaki, D M" sort="Togasaki, D M" uniqKey="Togasaki D" first="D. M." last="Togasaki">D. M. Togasaki</name><affiliation><mods:affiliation>The Parkinson's Institute, Sunnyvale, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Farahani, K F" sort="Farahani, K F" uniqKey="Farahani K" first="K. F." last="Farahani">K. F. Farahani</name><affiliation><mods:affiliation>Department of Radiological Sciences, UCLA School of Medicine, Los Angeles, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Delfani, K" sort="Delfani, K" uniqKey="Delfani K" first="K." last="Delfani">K. Delfani</name><affiliation><mods:affiliation>Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Janson, A M" sort="Janson, A M" uniqKey="Janson A" first="A. M." last="Janson">A. M. Janson</name><affiliation><mods:affiliation>Department of Neuroscience, Karolinska Institute, Stockholm, Sweden</mods:affiliation></affiliation></author><author><name sortKey="Phelps, M E" sort="Phelps, M E" uniqKey="Phelps M" first="M. E." last="Phelps">M. E. Phelps</name><affiliation><mods:affiliation>Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Langston, J W" sort="Langston, J W" uniqKey="Langston J" first="J. W." last="Langston">J. W. Langston</name><affiliation><mods:affiliation>The Parkinson's Institute, Sunnyvale, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Barrio, J R" sort="Barrio, J R" uniqKey="Barrio J" first="J. R." last="Barrio">J. R. Barrio</name><affiliation><mods:affiliation>Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="2001-09">2001-09</date><biblScope unit="vol">16</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="838">838</biblScope><biblScope unit="page" to="848">848</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">30BF6B3FD3C05C2EEA0624BCFD1583FA06C06E27</idno><idno type="DOI">10.1002/mds.1168</idno><idno type="ArticleID">MDS1168</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>6‐[F18]fluoro‐L‐DOPA</term><term>Parkinson's disease</term><term>optical fractionator</term><term>positron emission tomography</term><term>squirrel monkeys</term><term>stereology</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Striatal 6‐[18F]fluoro‐L‐DOPA (FDOPA) kinetic rate constants were measured by positron emission tomography (PET) in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐treated squirrel monkeys. After scanning, stereological counts of dopaminergic neurons were done in substantia nigra, and dopamine (DA) and metabolite concentrations were determined in the caudate, putamen, and substantia nigra. Graded doses of MPTP produced animals with mild to moderate reductions (10–35%) in dopaminergic neurons, where the percent of cell loss was proportional to the amount of MPTP given. Striatal DA and metabolite concentrations were relatively unchanged in animals given 1.0 and 1.5 mg/kg of MPTP, but were significantly reduced after 2.0 mg/kg of MPTP. All animals injected with a single dose of MPTP showed no overt signs of parkinsonism. In contrast, DA and metabolite concentrations in the substantia nigra were significantly reduced for all MPTP‐treated animals. Reduction of dopaminergic indices in the substantia nigra did not parallel reductions in the striatum, indicating differential sensitivity of the nigrostriatal pathway to the neurotoxic effects of MPTP. The percent change in FDOPA uptake (Ki) and decarboyxlation (k3) after MPTP showed significant positive correlations to striatal DA levels, but not to the number of dopaminergic neurons. This suggests that FDOPA is a good index of striatal DA levels. © 2001 Movement Disorder Society.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>R.E. Yee PhD</name><affiliations><json:string>Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California, USA</json:string></affiliations></json:item><json:item><name>I. Irwin PhD</name><affiliations><json:string>The Parkinson's Institute, Sunnyvale, California, USA</json:string></affiliations></json:item><json:item><name>C. Milonas MSc</name><affiliations><json:string>Department of Neuroscience, Karolinska Institute, Stockholm, Sweden</json:string></affiliations></json:item><json:item><name>D.B. Stout PhD</name><affiliations><json:string>Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California, USA</json:string></affiliations></json:item><json:item><name>S‐C. Huang DSc</name><affiliations><json:string>Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California, USA</json:string><json:string>Department of Biomathematics, UCLA School of Medicine, Los Angeles, California, USA</json:string></affiliations></json:item><json:item><name>K. Shoghi‐Jadid BS</name><affiliations><json:string>Department of Biomathematics, UCLA School of Medicine, Los Angeles, California, USA</json:string></affiliations></json:item><json:item><name>N. Satyamurthy PhD</name><affiliations><json:string>Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California, USA</json:string></affiliations></json:item><json:item><name>L.E. Delanney PhD</name><affiliations><json:string>The Parkinson's Institute, Sunnyvale, California, USA</json:string></affiliations></json:item><json:item><name>D.M. Togasaki MD, PhD</name><affiliations><json:string>The Parkinson's Institute, Sunnyvale, California, USA</json:string></affiliations></json:item><json:item><name>K.F. Farahani PhD</name><affiliations><json:string>Department of Radiological Sciences, UCLA School of Medicine, Los Angeles, California, USA</json:string></affiliations></json:item><json:item><name>K. Delfani PhD</name><affiliations><json:string>Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California, USA</json:string></affiliations></json:item><json:item><name>A.M. Janson MD, PhD</name><affiliations><json:string>Department of Neuroscience, Karolinska Institute, Stockholm, Sweden</json:string></affiliations></json:item><json:item><name>M.E. Phelps PhD</name><affiliations><json:string>Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California, USA</json:string></affiliations></json:item><json:item><name>J.W. Langston MD</name><affiliations><json:string>The Parkinson's Institute, Sunnyvale, California, USA</json:string></affiliations></json:item><json:item><name>J.R. Barrio PhD</name><affiliations><json:string>Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>positron emission tomography</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>6‐[F18]fluoro‐L‐DOPA</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>squirrel monkeys</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>stereology</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>optical fractionator</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Striatal 6‐[18F]fluoro‐L‐DOPA (FDOPA) kinetic rate constants were measured by positron emission tomography (PET) in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐treated squirrel monkeys. After scanning, stereological counts of dopaminergic neurons were done in substantia nigra, and dopamine (DA) and metabolite concentrations were determined in the caudate, putamen, and substantia nigra. Graded doses of MPTP produced animals with mild to moderate reductions (10–35%) in dopaminergic neurons, where the percent of cell loss was proportional to the amount of MPTP given. Striatal DA and metabolite concentrations were relatively unchanged in animals given 1.0 and 1.5 mg/kg of MPTP, but were significantly reduced after 2.0 mg/kg of MPTP. All animals injected with a single dose of MPTP showed no overt signs of parkinsonism. In contrast, DA and metabolite concentrations in the substantia nigra were significantly reduced for all MPTP‐treated animals. Reduction of dopaminergic indices in the substantia nigra did not parallel reductions in the striatum, indicating differential sensitivity of the nigrostriatal pathway to the neurotoxic effects of MPTP. The percent change in FDOPA uptake (Ki) and decarboyxlation (k3) after MPTP showed significant positive correlations to striatal DA levels, but not to the number of dopaminergic neurons. This suggests that FDOPA is a good index of striatal DA levels. © 2001 Movement Disorder Society.</abstract><qualityIndicators><score>7.46</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1448</abstractCharCount><pdfWordCount>6297</pdfWordCount><pdfCharCount>40798</pdfCharCount><pdfPageCount>11</pdfPageCount><abstractWordCount>205</abstractWordCount></qualityIndicators><title>Novel observations with FDOPA‐PET imaging after early nigrostriatal damage</title><genre><json:string>Serial article</json:string></genre><host><volume>16</volume><pages><total>11</total><last>848</last><first>838</first></pages><issn><json:string>0885-3185</json:string></issn><issue>5</issue><subject><json:item><value>Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2001</publicationDate><copyrightDate>2001</copyrightDate><doi><json:string>10.1002/mds.1168</json:string></doi><id>30BF6B3FD3C05C2EEA0624BCFD1583FA06C06E27</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/30BF6B3FD3C05C2EEA0624BCFD1583FA06C06E27/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/30BF6B3FD3C05C2EEA0624BCFD1583FA06C06E27/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/30BF6B3FD3C05C2EEA0624BCFD1583FA06C06E27/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Novel observations with FDOPA‐PET imaging after early nigrostriatal damage</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><availability><p>John Wiley & Sons, Inc.</p></availability><date>2001</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Novel observations with FDOPA‐PET imaging after early nigrostriatal damage</title><author><persName><forename type="first">R.E.</forename><surname>Yee</surname><roleName type="degree">PhD</roleName></persName><affiliation>Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California, USA</affiliation></author><author><persName><forename type="first">I.</forename><surname>Irwin</surname><roleName type="degree">PhD</roleName></persName><affiliation>The Parkinson's Institute, Sunnyvale, California, USA</affiliation></author><author><persName><forename type="first">C.</forename><surname>Milonas</surname><roleName type="degree">MSc</roleName></persName><affiliation>Department of Neuroscience, Karolinska Institute, Stockholm, Sweden</affiliation></author><author><persName><forename type="first">D.B.</forename><surname>Stout</surname><roleName type="degree">PhD</roleName></persName><affiliation>Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California, USA</affiliation></author><author><persName><forename type="first">S‐C.</forename><surname>Huang</surname><roleName type="degree">DSc</roleName></persName><affiliation>Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California, USA</affiliation><affiliation>Department of Biomathematics, UCLA School of Medicine, Los Angeles, California, USA</affiliation></author><author><persName><forename type="first">K.</forename><surname>Shoghi‐Jadid</surname><roleName type="degree">BS</roleName></persName><affiliation>Department of Biomathematics, UCLA School of Medicine, Los Angeles, California, USA</affiliation></author><author><persName><forename type="first">N.</forename><surname>Satyamurthy</surname><roleName type="degree">PhD</roleName></persName><affiliation>Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California, USA</affiliation></author><author><persName><forename type="first">L.E.</forename><surname>Delanney</surname><roleName type="degree">PhD</roleName></persName><affiliation>The Parkinson's Institute, Sunnyvale, California, USA</affiliation></author><author><persName><forename type="first">D.M.</forename><surname>Togasaki</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>The Parkinson's Institute, Sunnyvale, California, USA</affiliation></author><author><persName><forename type="first">K.F.</forename><surname>Farahani</surname><roleName type="degree">PhD</roleName></persName><affiliation>Department of Radiological Sciences, UCLA School of Medicine, Los Angeles, California, USA</affiliation></author><author><persName><forename type="first">K.</forename><surname>Delfani</surname><roleName type="degree">PhD</roleName></persName><affiliation>Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California, USA</affiliation></author><author><persName><forename type="first">A.M.</forename><surname>Janson</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>Department of Neuroscience, Karolinska Institute, Stockholm, Sweden</affiliation></author><author><persName><forename type="first">M.E.</forename><surname>Phelps</surname><roleName type="degree">PhD</roleName></persName><affiliation>Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California, USA</affiliation></author><author><persName><forename type="first">J.W.</forename><surname>Langston</surname><roleName type="degree">MD</roleName></persName><affiliation>The Parkinson's Institute, Sunnyvale, California, USA</affiliation></author><author><persName><forename type="first">J.R.</forename><surname>Barrio</surname><roleName type="degree">PhD</roleName></persName><affiliation>Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="2001-09"></date><biblScope unit="vol">16</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="838">838</biblScope><biblScope unit="page" to="848">848</biblScope></imprint></monogr><idno type="istex">30BF6B3FD3C05C2EEA0624BCFD1583FA06C06E27</idno><idno type="DOI">10.1002/mds.1168</idno><idno type="ArticleID">MDS1168</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2001</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Striatal 6‐[18F]fluoro‐L‐DOPA (FDOPA) kinetic rate constants were measured by positron emission tomography (PET) in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐treated squirrel monkeys. After scanning, stereological counts of dopaminergic neurons were done in substantia nigra, and dopamine (DA) and metabolite concentrations were determined in the caudate, putamen, and substantia nigra. Graded doses of MPTP produced animals with mild to moderate reductions (10–35%) in dopaminergic neurons, where the percent of cell loss was proportional to the amount of MPTP given. Striatal DA and metabolite concentrations were relatively unchanged in animals given 1.0 and 1.5 mg/kg of MPTP, but were significantly reduced after 2.0 mg/kg of MPTP. All animals injected with a single dose of MPTP showed no overt signs of parkinsonism. In contrast, DA and metabolite concentrations in the substantia nigra were significantly reduced for all MPTP‐treated animals. Reduction of dopaminergic indices in the substantia nigra did not parallel reductions in the striatum, indicating differential sensitivity of the nigrostriatal pathway to the neurotoxic effects of MPTP. The percent change in FDOPA uptake (Ki) and decarboyxlation (k3) after MPTP showed significant positive correlations to striatal DA levels, but not to the number of dopaminergic neurons. This suggests that FDOPA is a good index of striatal DA levels. © 2001 Movement Disorder Society.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>positron emission tomography</term></item><item><term>6‐[F18]fluoro‐L‐DOPA</term></item><item><term>squirrel monkeys</term></item><item><term>Parkinson's disease</term></item><item><term>stereology</term></item><item><term>optical fractionator</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2000-03-24">Received</change><change when="2000-11-06">Registration</change><change when="2001-09">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/30BF6B3FD3C05C2EEA0624BCFD1583FA06C06E27/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>John Wiley & Sons, Inc.</publisherName><publisherLoc>New York</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="50"><doi origin="wiley" registered="yes">10.1002/mds.v16:5</doi><numberingGroup><numbering type="journalVolume" number="16">16</numbering><numbering type="journalIssue">5</numbering></numberingGroup><coverDate startDate="2001-09">September 2001</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="80" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.1168</doi><idGroup><id type="unit" value="MDS1168"></id></idGroup><countGroup><count type="pageTotal" number="11"></count></countGroup><titleGroup><title type="articleCategory">Article</title><title type="tocHeading1">Article</title></titleGroup><copyright ownership="thirdParty">Copyright © 2001 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2000-03-24"></event><event type="manuscriptRevised" date="2000-08-02"></event><event type="manuscriptAccepted" date="2000-11-06"></event><event type="firstOnline" date="2001-08-30"></event><event type="publishedOnlineFinalForm" date="2001-10-12"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2001-08-30"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:3.3.0 mode:FullText" date="2014-03-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.3.0 mode:FullText" date="2014-03-24"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">838</numbering><numbering type="pageLast">848</numbering></numberingGroup><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS1168.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="5"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="60"></count><count type="wordTotal" number="6039"></count></countGroup><titleGroup><title type="main" xml:lang="en">Novel observations with FDOPA‐PET imaging after early nigrostriatal damage</title><title type="short" xml:lang="en">FDOPA Imaging of Early Nigrostriatal Damage</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>R.E.</givenNames><familyName>Yee</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af3"><personName><givenNames>I.</givenNames><familyName>Irwin</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af4"><personName><givenNames>C.</givenNames><familyName>Milonas</familyName><degrees>MSc</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>D.B.</givenNames><familyName>Stout</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>S‐C.</givenNames><familyName>Huang</familyName><degrees>DSc</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af2"><personName><givenNames>K.</givenNames><familyName>Shoghi‐Jadid</familyName><degrees>BS</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af1"><personName><givenNames>N.</givenNames><familyName>Satyamurthy</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af3"><personName><givenNames>L.E.</givenNames><familyName>Delanney</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af3"><personName><givenNames>D.M.</givenNames><familyName>Togasaki</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au10" creatorRole="author" affiliationRef="#af5"><personName><givenNames>K.F.</givenNames><familyName>Farahani</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au11" creatorRole="author" affiliationRef="#af1"><personName><givenNames>K.</givenNames><familyName>Delfani</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au12" creatorRole="author" affiliationRef="#af4"><personName><givenNames>A.M.</givenNames><familyName>Janson</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au13" creatorRole="author" affiliationRef="#af1"><personName><givenNames>M.E.</givenNames><familyName>Phelps</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au14" creatorRole="author" affiliationRef="#af3"><personName><givenNames>J.W.</givenNames><familyName>Langston</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au15" creatorRole="author" affiliationRef="#af1"><personName><givenNames>J.R.</givenNames><familyName>Barrio</familyName><degrees>PhD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California, USA</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Department of Biomathematics, UCLA School of Medicine, Los Angeles, California, USA</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>The Parkinson's Institute, Sunnyvale, California, USA</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="US" type="organization"><unparsedAffiliation>Department of Neuroscience, Karolinska Institute, Stockholm, Sweden</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="US" type="organization"><unparsedAffiliation>Department of Radiological Sciences, UCLA School of Medicine, Los Angeles, California, USA</unparsedAffiliation></affiliation><affiliation xml:id="corr1"><unparsedAffiliation>Department of Molecular and Medical Pharmacology, UCLA School of Medicine, B2‐086A Center of the Health Sciences, Los Angeles, CA 90095‐6948</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">positron emission tomography</keyword><keyword xml:id="kwd2">6‐[F<sup>18</sup>]fluoro‐L‐DOPA</keyword><keyword xml:id="kwd3">squirrel monkeys</keyword><keyword xml:id="kwd4">Parkinson's disease</keyword><keyword xml:id="kwd5">stereology</keyword><keyword xml:id="kwd6">optical fractionator</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Striatal 6‐[<sup>18</sup>F]fluoro‐L‐DOPA (FDOPA) kinetic rate constants were measured by positron emission tomography (PET) in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐treated squirrel monkeys. After scanning, stereological counts of dopaminergic neurons were done in substantia nigra, and dopamine (DA) and metabolite concentrations were determined in the caudate, putamen, and substantia nigra. Graded doses of MPTP produced animals with mild to moderate reductions (10–35%) in dopaminergic neurons, where the percent of cell loss was proportional to the amount of MPTP given. Striatal DA and metabolite concentrations were relatively unchanged in animals given 1.0 and 1.5 mg/kg of MPTP, but were significantly reduced after 2.0 mg/kg of MPTP. All animals injected with a single dose of MPTP showed no overt signs of parkinsonism. In contrast, DA and metabolite concentrations in the substantia nigra were significantly reduced for all MPTP‐treated animals. Reduction of dopaminergic indices in the substantia nigra did not parallel reductions in the striatum, indicating differential sensitivity of the nigrostriatal pathway to the neurotoxic effects of MPTP. The percent change in FDOPA uptake (Ki) and decarboyxlation (k<sub>3</sub>) after MPTP showed significant positive correlations to striatal DA levels, but not to the number of dopaminergic neurons. This suggests that FDOPA is a good index of striatal DA levels. © 2001 Movement Disorder Society.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Novel observations with FDOPA‐PET imaging after early nigrostriatal damage</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>FDOPA Imaging of Early Nigrostriatal Damage</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Novel observations with FDOPA‐PET imaging after early nigrostriatal damage</title></titleInfo><name type="personal"><namePart type="given">R.E.</namePart><namePart type="family">Yee</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">I.</namePart><namePart type="family">Irwin</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>The Parkinson's Institute, Sunnyvale, California, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Milonas</namePart><namePart type="termsOfAddress">MSc</namePart><affiliation>Department of Neuroscience, Karolinska Institute, Stockholm, Sweden</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D.B.</namePart><namePart type="family">Stout</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S‐C.</namePart><namePart type="family">Huang</namePart><namePart type="termsOfAddress">DSc</namePart><affiliation>Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California, USA</affiliation><affiliation>Department of Biomathematics, UCLA School of Medicine, Los Angeles, California, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K.</namePart><namePart type="family">Shoghi‐Jadid</namePart><namePart type="termsOfAddress">BS</namePart><affiliation>Department of Biomathematics, UCLA School of Medicine, Los Angeles, California, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N.</namePart><namePart type="family">Satyamurthy</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L.E.</namePart><namePart type="family">Delanney</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>The Parkinson's Institute, Sunnyvale, California, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D.M.</namePart><namePart type="family">Togasaki</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>The Parkinson's Institute, Sunnyvale, California, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K.F.</namePart><namePart type="family">Farahani</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Radiological Sciences, UCLA School of Medicine, Los Angeles, California, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K.</namePart><namePart type="family">Delfani</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A.M.</namePart><namePart type="family">Janson</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neuroscience, Karolinska Institute, Stockholm, Sweden</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.E.</namePart><namePart type="family">Phelps</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.W.</namePart><namePart type="family">Langston</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>The Parkinson's Institute, Sunnyvale, California, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.R.</namePart><namePart type="family">Barrio</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>John Wiley & Sons, Inc.</publisher><place><placeTerm type="text">New York</placeTerm></place><dateIssued encoding="w3cdtf">2001-09</dateIssued><dateCaptured encoding="w3cdtf">2000-03-24</dateCaptured><dateValid encoding="w3cdtf">2000-11-06</dateValid><copyrightDate encoding="w3cdtf">2001</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">5</extent><extent unit="tables">2</extent><extent unit="references">60</extent><extent unit="words">6039</extent></physicalDescription><abstract lang="en">Striatal 6‐[18F]fluoro‐L‐DOPA (FDOPA) kinetic rate constants were measured by positron emission tomography (PET) in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐treated squirrel monkeys. After scanning, stereological counts of dopaminergic neurons were done in substantia nigra, and dopamine (DA) and metabolite concentrations were determined in the caudate, putamen, and substantia nigra. Graded doses of MPTP produced animals with mild to moderate reductions (10–35%) in dopaminergic neurons, where the percent of cell loss was proportional to the amount of MPTP given. Striatal DA and metabolite concentrations were relatively unchanged in animals given 1.0 and 1.5 mg/kg of MPTP, but were significantly reduced after 2.0 mg/kg of MPTP. All animals injected with a single dose of MPTP showed no overt signs of parkinsonism. In contrast, DA and metabolite concentrations in the substantia nigra were significantly reduced for all MPTP‐treated animals. Reduction of dopaminergic indices in the substantia nigra did not parallel reductions in the striatum, indicating differential sensitivity of the nigrostriatal pathway to the neurotoxic effects of MPTP. The percent change in FDOPA uptake (Ki) and decarboyxlation (k3) after MPTP showed significant positive correlations to striatal DA levels, but not to the number of dopaminergic neurons. This suggests that FDOPA is a good index of striatal DA levels. © 2001 Movement Disorder Society.</abstract><subject lang="en"><genre>Keywords</genre><topic>positron emission tomography</topic><topic>6‐[F18]fluoro‐L‐DOPA</topic><topic>squirrel monkeys</topic><topic>Parkinson's disease</topic><topic>stereology</topic><topic>optical fractionator</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><detail type="issue"><caption>no.</caption><number>5</number></detail><extent unit="pages"><start>838</start><end>848</end><total>11</total></extent></part></relatedItem><identifier type="istex">30BF6B3FD3C05C2EEA0624BCFD1583FA06C06E27</identifier><identifier type="DOI">10.1002/mds.1168</identifier><identifier type="ArticleID">MDS1168</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2001 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>John Wiley & Sons, Inc.</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000534 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000534 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:30BF6B3FD3C05C2EEA0624BCFD1583FA06C06E27
|texte= Novel observations with FDOPA‐PET imaging after early nigrostriatal damage
}}
| This area was generated with Dilib version V0.6.23. |  |